Shanghai ST-segment Elevation Myocardial Infarction Cohort

Ruijin Hospital2,000 enrolled

Overview

ST-segment elevation myocardial infarction(STEMI) remains a major cause of morbidity and mortality worldwide, despite of the early reperfusion therapy, including fibrinolysis, primary percutaneous coronary intervention (PCI),and standardized medical treatment.To improve the prognosis of STEMI patients, the management in their hospitalization should be optimized, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through PCI (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as lipid-lowering therapy. This study aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

This study is a prospective cohort study. It aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

ST Elevation Myocardial Infarction

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ST elevation myocardial infarction * Coronary angiography and percutaneous coronary intervention within 12 hours of symptom onset * Capable and willing to provide informed conset and capable of completing study visits Exclusion Criteria: * Cardiovascular shock at admission * Severe physical disability * Active malignant tumors * Active autoimmune diseases